2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175557
    PI4K-IN-2 2411491-16-0 98%
    PI4K-IN-2 (Compound 30) is a highly selective type III phosphatidylinositol 4-kinase β (PI4KB) inhibitor (IC50=0.015 μM). PI4K-IN-2 is promising for research of human rhinovirus (HRV).
    PI4K-IN-2
  • HY-175559
    TTHP 512
    TTHP 512 is an influenza A virus (IAV) inhibitor. TTHP 512 demonstrates significant antiviral activity with an IC50 value of 1.46 μM. TTHP 512 inhibits the expression of viral nucleoprotein (NP) and PB2 protein, thereby disrupting the viral replication process. TTHP 512 is promising for research of influenza A virus.
    TTHP 512
  • HY-175561
    HIV-IN-12 98%
    HIV-IN-12 (Compound A1) is a dual HIV-1 Vif and reverse transcriptase (RT) inhibitor. HIV-IN-12 is promising for research of HIV infections.
    HIV-IN-12
  • HY-175596
    ACP1-01 1382489-31-7 98%
    ACP1-01 is a bacterial ClpP activator with EC50s of 3.4 and 2.6  μM for Neisseria meningitides ClpP (NmClpP) and Escherichia coli ClpP (EcClpP). ACP1-01 noncovalently binds to ClpP C sites and activates the protease. ACP1-01 has antibacterial activity. ACP1-01 can be used for bacterial infections research.
    ACP1-01
  • HY-175597
    ClpP modulator-1 2363753-48-2
    ClpP modulator-1 (Compound BC8a), a peptidomimetic, is an allosteric ClpP modulator. ClpP modulator-1 is a ClpP activator at low concentration with EC50s of 0.35 and 0.58  μM for for Neisseria meningitides ClpP (NmClpP) and Escherichia coli ClpP (EcClpP), resepectively. ClpP modulator-1 also inhibits peptidase activity at high concentration by competitively inhibiting substrate protein (LY-AMC) binding to ClpP C sites. ClpP modulator-1 has antibacterial activity. ClpP modulator-1 can be used for bacterial infections research.
    ClpP modulator-1
  • HY-175607
    AChE/nAChR-IN-1 59417-09-3 98%
    AChE/nAChR-IN-1 (Compound 1a) is dual-functional inhibitor of AChE and nAChR. AChE/nAChR-IN-1 has potent toxicity and larvicidal effectiveness against Culex pipiens larvae with a LC50 of 4 ng/mL. AChE/nAChR-IN-1 can be used as larvicides for mosquito-borne diseases research.
    AChE/nAChR-IN-1
  • HY-17560R
    Demeclocycline hydrochloride (Standard) 64-73-3
    Demeclocycline hydrochloride (Standard) is the analytical standard of Demeclocycline hydrochloride (HY-17560). This product is intended for research and analytical applications. Demeclocycline hydrochloride is an orally active tetracycline antibiotic that inhibits the binding of aminoacyl tRNA by binding to the 30S ribosomal subunit, thereby affecting protein synthesis. Demeclocycline hydrochloride exhibits antibacterial activity against a broad spectrum of bacterial infections.
    Demeclocycline hydrochloride (Standard)
  • HY-175647
    Myosin-5-IN-2 98%
    Myosin-5-IN-2 (Compound G19) is a Myosin-5 inhibitor. Myosin-5-IN-2 has an antifungal activity against Fusarium graminearum (Fg), Botrytis cinerea and Rhizoctonia solani with an EC50 s of 0.326 μg/mL for Fg. Myosin-5-IN-2 has effective protective and curative control efficiency for wheat leaves. Myosin-5-IN-2 severely damages the surface integrity of mycelial cells and induces cytoplasmic leakage. Myosin-5-IN-2 can be used for fungal infections like fusarium head blight (FHB) research.
    Myosin-5-IN-2
  • HY-175648
    Antiparasitic agent-28
    Antiparasitic agent-28 is an orally active, selective inhibitor of Toxoplasma gondii phenylalanine tRNA synthetase (TgcPheRS) with blood-brain barrier penetration. Antiparasitic agent-28 inhibits the growth of T. gondii tachyzoites (TgME49-Fluc strain) an (EC50 = 1 nM) and T. gondii bradyzoites (Tg68nLuc strain) induced by alkaline (EC50 = 3 nM) and glutamine-rich medium (EC50 = 0.1 nM). Antiparasitic agent-28 demonstrates potent anti-toxoplasmosis efficacy in mice infected with TgME49-Fluc tachyzoites. Antiparasitic agent-28 can be used for the study of Toxoplasma gondii infection.
    Antiparasitic agent-28
  • HY-175667
    NNRT-IN-12
    NNRT-IN-12 (compound 19) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 value of 0.107 μM for WT HIV-1 RT. NNRT-IN-12 shows anti-HIV-1 activity with EC50 value of 14.1, 5.03, 7.64, 27.1 nM for L100I, K103N, Y181C, Y188L mutant HIV-1 strains, respectively. NNRT-IN-12 shows cytotoxicity.
    NNRT-IN-12
  • HY-175683
    EBV-IN-1
    EBV-IN-1 (Compound 15) is an antiviral agent. EBV-IN-1 has a potent antiviral activity against EBV with a EC50 of 0.17  μM. EBV-IN-1 also shows inhibitory effects on HIV (EC50: 20.8 μM). EBV-IN-1 can be used for EBV and HIV infections research.
    EBV-IN-1
  • HY-175697
    Glycosyltransferase-IN-2
    Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC50s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits RNA replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research.
    Glycosyltransferase-IN-2
  • HY-175699
    Antimicrobial agent-42
    Antimicrobial agent-42 (Compound 6j) is an antimicrobial agent. Antimicrobial agent-42 interacts with key amino acids such as Lys59 and Ser170 within the ALS3 protein, crucial for the binding of host peptides. Antimicrobial agent-42 significantly inhibits Candida albicans biofilm formation and reduces planktonic cells aggregation and hyphal formation. Antimicrobial agent-42 has an antifungal activity, promising for fungal infections reseach.
    Antimicrobial agent-42
  • HY-175712
    SARS-CoV-2 Mpro-IN-47
    SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2.
    SARS-CoV-2 Mpro-IN-47
  • HY-175722
    JSZ16
    JSZ16 is a Succinate dehydrogenase (SDH) inhibitor with an IC50 of 30.3  μM. JSZ16 has potent broad-spectrum fungicidal activity, such as Sclerotinia sclerotiorum, Botrytis cinerea and Colletotrichum fragariae, with an EC50 of 4.4 mg/L for Sclerotinia sclerotiorum. JSZ16 influences the cell membrane permeability of pathogenic fungi. JSZ16 can be used for the development of fungicide.
    JSZ16
  • HY-175723
    MAO-A/B-IN-4
    MAO-A/B-IN-4 is an orally active MAO-A/B inhibitor, with IC50 values of 51.3 μM and 47.0 μM, respectively. MAO-A/B-IN-4 exhibits potent activity against S. aureus, MSSA, MRSA, LRSA, and LREFa. MAO-A/B-IN-4 demonstrates potent antibacterial efficacy in a mouse model of LRSA peritonitis infection. MAO-A/B-IN-4 can be used for the study of bacterial infections.
    MAO-A/B-IN-4
  • HY-175724
    MBL-IN-6
    MBL-IN-6 (Compound 6d) is a Metallo-β-lactamase (MBL) inhibitor with Kis of 2.6 and 0.08 μM for NDM-1 and VIM-2, respectively. MBL-IN-6 has a synergistic activities with Imipenem (HY-B1369A) on MBL-producing clinical isolates (such as E. coli SI-M001, K. pneumonia T2301 and S. marcescens SI-1591) with MICs of 2-64 μg/mL. MBL-IN-6 does not have off-target effects without ACE-1 inhibition activity. MBL-IN-6 can be used for antimicrobial resistance research.
    MBL-IN-6
  • HY-175731
    FabX-IN-1 98%
    FabX-IN-1 (Compound 47) is a selective FabX inhibitor with an IC50 of 0.128  μM. FabX-IN-1 has a narrow-spectrum antibacterial activity against Helicobacter pylori with a MIC of 64 μg/mL, but significantly enhances synergistic inhibitory efficacy combined with membrane permeabilizers, efflux pump inhibitors, and Clarithromycin (HY-17508). FabX-IN-1 can be used for bacterial infections research.
    FabX-IN-1
  • HY-175732
    PI4Kβ-IN-1
    PI4Kβ-IN-1 is an orally active and selective PI4Kβ inhibitor, with an IC50 of 0.9 nM. PI4Kβ-IN-1 exhibits inhibitory activity against all stages of the P. falciparum life cycle, including blood, liver, and transmission stages. PI4Kβ-IN-1 demonstrates potent antimalarial efficacy in the mouse model infected with Plasmodium falciparum. PI4Kβ-IN-1 can be used for the study of malaria caused by Plasmodium falciparum.
    PI4Kβ-IN-1
  • HY-175740
    Antiviral agent 71
    Antiviral agent 71 (Compound 26) is an antiviral agent. Antiviral agent 71 has a broad-spectrum enterovirus antiviral activity, such as EV-D68, Echo-11 and HRV-14 with EC50s of 0.017-4.1 μM. EV-D68-IN-1 can be used for non-polio enteroviruses (NPEV) infections research.
    Antiviral agent 71
Cat. No. Product Name / Synonyms Application Reactivity